Tango Therapeutics/TNGX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Tango Therapeutics

Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. Its lead program, TNG908, is an methylthioadenosine (MTA)-cooperative inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to work selectively in cancer cells with an methylthioadenosine phosphorylase (MTAP) deletion. Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor. The Company's programs also include TNG348 and TNG462. TNG348 is an allosteric inhibitor of ubiquitin-specific protease (USP1).

Ticker

TNGX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Barbara Weber

Employees

140

Headquarters

Boston, United States

TNGX Metrics

BasicAdvanced
$739M
Market cap
-
P/E ratio
-$1.11
EPS
0.80
Beta
-
Dividend rate
$739M
0.80363
$13.03
$2.56
623K
8.227
-27.57%
-45.41%
-31.29%
19.859
2.793
2.796
49.72%
12.18%

What the Analysts think about TNGX

Analyst Ratings

Majority rating from 8 analysts.
Buy

TNGX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-592.18% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$6.4M
18.52%
Net income
-$38M
23.45%
Profit margin
-592.18%
4.16%

TNGX Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 11.90%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.23
-$0.23
-$0.32
-$0.35
-
Expected
-$0.34
-$0.35
-$0.28
-$0.31
-$0.34
Surprise
-31.55%
-33.33%
15.21%
11.90%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Tango Therapeutics stock?

Tango Therapeutics (TNGX) has a market cap of $739M as of June 17, 2024.

What is the P/E ratio for Tango Therapeutics stock?

The price to earnings (P/E) ratio for Tango Therapeutics (TNGX) stock is 0 as of June 17, 2024.

Does Tango Therapeutics stock pay dividends?

No, Tango Therapeutics (TNGX) stock does not pay dividends to its shareholders as of June 17, 2024.

When is the next Tango Therapeutics dividend payment date?

Tango Therapeutics (TNGX) stock does not pay dividends to its shareholders.

What is the beta indicator for Tango Therapeutics?

Tango Therapeutics (TNGX) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Tango Therapeutics stock price target?

The target price for Tango Therapeutics (TNGX) stock is $14.86, which is NaN% below the current price of $. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Tango Therapeutics stock

Buy or sell Tango Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing